X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PANACEA BIOTECH - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PANACEA BIOTECH GLENMARK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 19.0 -7.4 - View Chart
P/BV x 3.4 4.0 84.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
PANACEA BIOTECH
Mar-18
GLENMARK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs930364 255.5%   
Low Rs517129 400.8%   
Sales per share (Unadj.) Rs322.696.8 333.3%  
Earnings per share (Unadj.) Rs28.5-12.4 -229.6%  
Cash flow per share (Unadj.) Rs39.2-2.9 -1,373.9%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.050.4 363.1%  
Shares outstanding (eoy) m282.1761.25 460.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.5 88.1%   
Avg P/E ratio x25.4-19.9 -127.8%  
P/CF ratio (eoy) x18.5-86.4 -21.4%  
Price / Book Value ratio x4.04.9 80.8%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,20615,101 1,352.3%   
No. of employees `00013.72.5 555.8%   
Total wages/salary Rs m18,7181,516 1,234.8%   
Avg. sales/employee Rs Th6,636.82,401.9 276.3%   
Avg. wages/employee Rs Th1,364.7614.2 222.2%   
Avg. net profit/employee Rs Th586.1-307.9 -190.3%   
INCOME DATA
Net Sales Rs m91,0315,928 1,535.6%  
Other income Rs m91482 1,110.6%   
Total revenues Rs m91,9456,010 1,529.8%   
Gross profit Rs m16,154845 1,911.0%  
Depreciation Rs m3,019585 515.8%   
Interest Rs m2,8561,006 283.9%   
Profit before tax Rs m11,193-664 -1,687.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,15599 3,199.4%   
Profit after tax Rs m8,039-760 -1,057.7%  
Gross profit margin %17.714.3 124.4%  
Effective tax rate %28.2-14.9 -189.6%   
Net profit margin %8.8-12.8 -68.9%  
BALANCE SHEET DATA
Current assets Rs m69,8875,603 1,247.2%   
Current liabilities Rs m32,8796,910 475.8%   
Net working cap to sales %40.7-22.0 -184.4%  
Current ratio x2.10.8 262.1%  
Inventory Days Days81206 39.6%  
Debtors Days Days9384 111.6%  
Net fixed assets Rs m28,8929,941 290.6%   
Share capital Rs m28261 460.4%   
"Free" reserves Rs m51,3533,026 1,697.3%   
Net worth Rs m51,6353,087 1,672.7%   
Long term debt Rs m41,4185,707 725.7%   
Total assets Rs m125,95416,076 783.5%  
Interest coverage x4.90.3 1,445.6%   
Debt to equity ratio x0.81.8 43.4%  
Sales to assets ratio x0.70.4 196.0%   
Return on assets %8.61.5 565.7%  
Return on equity %15.6-24.6 -63.2%  
Return on capital %15.13.9 385.5%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m36,3171,600 2,269.8%   
Fx outflow Rs m9,7201,131 859.0%   
Net fx Rs m26,598469 5,676.1%   
CASH FLOW
From Operations Rs m16,4811,180 1,396.4%  
From Investments Rs m-10,133553 -1,832.8%  
From Financial Activity Rs m-4,685-1,644 285.1%  
Net Cashflow Rs m1,77090 1,973.2%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.6 1,150.0%  
FIIs % 34.4 1.3 2,646.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.6 44.5%  
Shareholders   56,727 10,259 552.9%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  VENUS REMEDIES  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS